Home › NDC Lookup › RxCUI directory › RxCUI 1087459

12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Rele... — RxCUI 1087459

RxNorm drug concept · Semantic clinical drug
RxCUI 1087459 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1087459
Official name12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ashydrocodone polistirex 10 MG / chlorpheniramine polistirex 8 MG per 5 ML 12HR Extended Release Oral Suspension; HYDROcodone polistirex 10 MG / chlorpheniramine polistirex 8 MG in 5 mL 12HR Extended Release Oral Suspension
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,375 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Hydrocodone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Hydrocodone extended-release is for severe, persistent pain that needs an around-the-clock opioid when other treatments haven't worked or aren't enough. It isn't meant for as-neede...
  • Swallow it whole, by mouth. Never crush, chew, cut or dissolve it, since that can release a dangerous dose at once. The capsules are taken about every 12 hours and the tablets once...
  • No. Alcohol can raise hydrocodone levels and cause a potentially fatal overdose. Avoid alcohol-containing products too, and check with me before combining it with sleep aids, anxie...
  • Nausea, constipation, vomiting, dizziness, headache, sleepiness and fatigue are the most common. Call for help right away if breathing slows, you can't stay awake, or you faint.
📖 Read our full Hydrocodone guide →

🕸️ Concept Web — How 12 HR chlorpheniramine polistirex 1.6 MG/ML / hy... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension RxCUI 1087459

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Chlorpheniramine 2400
    • Hydrocodone 5489
    • Chlorpheniramine / hydrocodone 214392
    • Chlorpheniramine polistirex 221074
    • Hydrocodone polistirex 221107
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tussionex 544165
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Chlorpheniramine / hydrocodone Extended Release Suspension 378790
    • Chlorpheniramine polistirex / hydrocodone polistirex Extended Release Suspension 2645875
    • Chlorpheniramine / hydrocodone Oral Liquid Product 1154770
    • Chlorpheniramine / hydrocodone Oral Product 1154771
    • Chlorpheniramine polistirex / hydrocodone polistirex Oral Liquid Product 2661687
    • Chlorpheniramine polistirex / hydrocodone polistirex Oral Product 2661441
    • Chlorpheniramine / hydrocodone Extended Release Suspension [Tussionex] 1087462
    • Chlorpheniramine polistirex / hydrocodone polistirex Extended Release Suspension [Tussionex] 2658204
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Chlorpheniramine polistirex 1.6 MG/ML 1145788
    • Hydrocodone polistirex 2 MG/ML 1145789
    • 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension [Tussionex] 1087463
    • Chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML [Tussionex] 1489775

Showing up to 8 concepts per family — 18 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Chlorpheniramine polistirex 1.6 MG/ML SCDC · 1145788
  • Hydrocodone polistirex 2 MG/ML SCDC · 1145789
  • Chlorpheniramine / hydrocodone Extended Release Suspension SCDF · 378790
  • Chlorpheniramine polistirex / hydrocodone polistirex Extended Release Suspension SCDFP · 2645875
  • Chlorpheniramine / hydrocodone Oral Liquid Product SCDG · 1154770
  • Chlorpheniramine / hydrocodone Oral Product SCDG · 1154771
  • Chlorpheniramine polistirex / hydrocodone polistirex Oral Liquid Product SCDGP · 2661687
  • Chlorpheniramine polistirex / hydrocodone polistirex Oral Product SCDGP · 2661441

Brand-Name Concepts

  • 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension [Tussionex] SBD · 1087463
  • Chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML [Tussionex] SBDC · 1489775
  • Chlorpheniramine / hydrocodone Extended Release Suspension [Tussionex] SBDF · 1087462
  • Chlorpheniramine polistirex / hydrocodone polistirex Extended Release Suspension [Tussionex] SBDFP · 2658204
  • Tussionex Oral Liquid Product SBDG · 1186708
  • Tussionex Oral Product SBDG · 1186709
  • Tussionex BN · 544165

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 1087459 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
27808-0086-01 1 BOTTLE, UNIT-DOSE in 1 CARTON (27808-086-01) / 115 mL in... Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Cranbury Pharmaceuticals, LLC 2015-03-06
27808-0086-02 473 mL in 1 BOTTLE (27808-086-02) Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Cranbury Pharmaceuticals, LLC 2015-03-06
63629-2303-01 1 BOTTLE, UNIT-DOSE in 1 CARTON (63629-2303-1) / 115 mL in... Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Bryant Ranch Prepack 2015-03-06
63629-2304-01 473 mL in 1 BOTTLE, UNIT-DOSE (63629-2304-1) Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Bryant Ranch Prepack 2015-03-06
72162-1283-02 115 mL in 1 BOTTLE (72162-1283-2) Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Bryant Ranch Prepack 2023-04-21
72162-1283-04 473 mL in 1 BOTTLE (72162-1283-4) Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release Bryant Ranch Prepack 2023-04-21
Observed labelers: Bryant Ranch Prepack (4) · Cranbury Pharmaceuticals, LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$0.5816
Range $0.4820–$0.6812 · middle 50% $0.5318–$0.6314 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.